Animal pharmaceutical company Zoetis experienced a more than 20% drop in its stock price, hitting a five-year low, after missing its first-quarter results and cutting its profit forecast. The company cited cautious consumer spending, leading pet owners to delay routine visits and higher-end pet treatments, as a contributing factor.